lusutrombopag - Rezultatele cautarii

Uniunea Europeană - română - EMA (European Medicines Agency)

mulpleo (previously lusutrombopag shionogi)

shionogi b.v. - lusutrombopag - trombocitopenie - hemostatice - mulpleo este indicat pentru tratamentul trombocitopeniei severe la pacienții adulți cu boală hepatică cronică supuși unei proceduri invazive.

Uniunea Europeană - română - EMA (European Medicines Agency)

doptelet

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocitopenie - hemostatice - doptelet este indicat pentru tratamentul trombocitopeniei severe la pacienții adulți cu boală hepatică cronică, care sunt programate să se supună unei proceduri invazive. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. corticosteroizi, imunoglobuline).

Uniunea Europeană - română - EMA (European Medicines Agency)

revolade

novartis europharm limited - eltrombopag - purpură, trombocitopenică, idiopatică - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 și 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 și 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.